M
Michele Caraglia
Researcher at Seconda Università degli Studi di Napoli
Publications - 562
Citations - 24508
Michele Caraglia is an academic researcher from Seconda Università degli Studi di Napoli. The author has contributed to research in topics: Cancer & Cancer cell. The author has an hindex of 67, co-authored 525 publications receiving 20615 citations. Previous affiliations of Michele Caraglia include Temple University & Magna Græcia University.
Papers
More filters
Journal ArticleDOI
Polydatin (3,4’,5-trihydroxystilbene-3-β-d-glucoside) is a new inhibitor of glucose-6-phosphate dehydrogenase affecting cancer metabolism and producing a strong cytotoxic and antimetastatic effect
Vincenzo Desiderio,Luigi Mele,Marcella La Noce,Virginia Tirino,Francesca Paino,Gabriellla Aquino,Antonio Barbieri,Silvana Papagerakis,David Boocok,Paola Stiuso,Michele Caraglia,Gianpaolo Papaccio +11 more
TL;DR: It is shown that Polydatin exerts a significant inhibitory effect on pentose phosphate pathway inhibiting HNSCC growth and metastases, pointing out that polydatin may be a reliable anticancer drug.
Journal ArticleDOI
Gene signatures predictive of response to radiotherapy in prostate cancer: a new step towards precision medicine
TL;DR: EndoPredict can predict whether breast cancer will spread in women with estrogen receptor positive, HER2 negative (ER+/HER2–) disease and that was recently demonstrated to give higher performance if compared with the other well established genotyping system Oncotype.
Journal ArticleDOI
Sarcomatoid larynx carcinoma differential clinical evolution, on field statistical considerations.
Filippo Ricciardiello,Marco Bocchetti,Raul Pellini,Remo Palladino,Michele Caraglia,Amedeo Boscaino,Gerardo Petruzzi,Francesco Jacopo Romano,Bruno Chiurazzi,Raffaele Addeo,Salvatore Mazzone,Massimo Mesolella,Flavia Oliva,Brigida Iorio +13 more
TL;DR: In this paper, the authors focused on the early and advanced stages of laryngeal spindle cell larynx carcinoma (SpCC) and highlighted the differences with Laryngegeal Squamous Cell Carcinoma (LSCC) focusing on clinical features, treatments, follow-up and survival in a patient's cohort composed by comparable cases from two subgroups.